How much revenue does Mingyue Optical Lens make?

Mingyue Optical Lens reported 770.30 million CNY in revenue for fiscal year 2024, up 2.9% from 748.74 million CNY in fiscal year 2023. In Q2 2025 revenue was 202.03 million CNY.

What is Mingyue Optical Lens's largest business segment?

Optical Products Division, with 757.95 million CNY or 87% of segment revenue in fiscal year 2025. Next: Raw Material Segment (13%).

Where does Mingyue Optical Lens make most of its revenue?

China: 97% of revenue by region in fiscal year 2025, followed by Foreign (3%).

What companies are similar to Mingyue Optical Lens?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS), Autek China Inc. (300595.SZ), Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS), BMC Medical Co., Ltd. (301367.SZ).

Mingyue Optical Lens Co.,Ltd. (301101.SZ) Stock

About Mingyue Optical Lens Co.,Ltd.

Mingyue Optical Lens Co.,Ltd. engages in the research and development, design, and production of lenses, lens raw materials, finished mirrors, and frames in China and internationally. The company offers myopia management for teenagers, progressive multifocal lenses, photochromic lenses, custom lenses, anti-fatigue lenses, outdoor polarized myopia sunglasses, KR lenses, post-operative protection le...

At a glance

Mingyue Optical Lens reported revenue of 770.30 million CNY for fiscal year 2024, up 2.9% from fiscal year 2023, and net income of 176.79 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 202.03 million CNY, up 4.7% from a year before. Its largest business segment, Optical Products Division, brought in 87% of segment revenue in fiscal year 2025; China was the largest region with 97%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.